CLDI News & Events

Calidi Biotherapeutics will present new data at the American Association of Cancer Research, AACR, annual meeting in San Diego, California on April 21 2026. The Company showcased new data on CLD-401, a systemically delivered oncolytic virus that is designed to express high levels of IL-15 superagonist only in the tumor microenvironment, currently in IND-enabling studies. The Company expects to file an IND for CLD-401 by the end of 2026. Data at AACR detailed the immune changes in the TME induced by CLD-401 including the recruitment and activation of NK, NK-T, and gamma delta (gammadelta) T-cells that lead to a therapeutic response in the immunocompetent animal models. In addition to IL-15 SA delivery with CLD-401, the RedTail platform has also been shown to enable in situ expression of tumor-targeted T cell engagers, as demonstrated in a separate AACR presentation focused on the CLD-501 program

Calidi Biotherapeutics presented new data at the American Association of Cancer Research, AACR, annual meeting in San Diego, California on April 19, 2026. The Company demonstrated new data on its approach of simultaneously activating T-cells while inducing the expression of T-cell engagers specifically in situ in the tumor microenvironment, TME. RedTail is Calidi's systemically delivered virotherapy platform designed to selectively target tumors, remodel the TME, and enable high-level expression of therapeutic genetic payloads directly at the tumor site while limiting peripheral exposure. CLD-401, the lead candidate derived from the RedTail platform, is engineered to express high levels of IL-15 superagonist, a known CD8 T-cell, NK cell, and gamma delta T-cell activator, in the TME. The Company expects to file an IND for CLD-401 by the end of 2026.

Calidi Biotherapeutics presented on its proprietary manufacturing process for CLD-401 at the BioProcessing Summit in Barcelona. RedTail is Calidi's systemically delivered virotherapy platform designed to selectively target tumor cells, remodel the tumor microenvironment, and enable high-level expression of therapeutic genetics at the tumor. CLD-401 is designed to reach metastatic sites, replicate only in tumor cells, and express high levels of IL-15 superagonist, a known T-cell and Natural Killer cell activator, in the TME. "The process discussed today highlights key scalability properties of the manufacturing system we have developed for the RedTail platform and CLD-401" said Antonio Santidrian, PhD, Chief Scientific Officer and Head of Technical Operations at Calidi. "Based on our interactions with the FDA, we believe this process can be used to support CLD-401 through clinical development with the ultimate goal of commercialization."

Calidi Biotherapeutics announced the pricing of its underwritten public offering of 10,519,631 units, with each unit consisting of one share of common stock, one 6 month warrant to purchase one share of common stock, one 12 month warrant to purchase one share of common stock and one five year warrant to purchase one share of common stock. Ladenburg Thalmann & Co. Inc. is acting as sole book-running manager for the offering. Each unit is being sold to the public at a price of $0.50 per unit and each pre-funded unit is being sold to the public at the public offering price of each unit less the $0.001 per share nominal exercise price for each pre-funded warrant. The gross proceeds to the Company from this offering are expected to be approximately $5.2M, before deducting underwriting discounts and commissions and other estimated offering expenses. The Company has granted the underwriter a 45-day option to purchase up to an additional 1,575,000 shares of common stock and/or warrants to purchase up to 1,575,000 shares of common stock for each series of warrants described above, or any combination thereof, solely to cover over-allotments, if any, at the public offering price, less underwriting discounts and commissions.This offering is expected to close on or about March 9, 2026, subject to the satisfaction of customary closing conditions.